Gardasil是世界上销量第二大的疫苗，但是在推广中仍然遇到很多困难。欧盟本周三宣布批准Gardasil用于预防由HPV引起的肛癌等疾病。这也为Gardasil进一步推广扫清了一大障碍。根据调查欧洲每年新增6800例肛癌患者，而这些患者中有75%-80%是由HPV病毒引起的。目前世界上许多国家都对HPV严阵以待，如澳大利亚此前就已经批准Gardasil用于防护青少年不受HPV影响。欧盟的这一决定将很大程度上刺激Gardasil的销售。现在欧洲只有英国只推荐12-13岁的少女接种该疫苗。赛诺菲的Dr.Jean-PaulKress表示，预防HPV感染是防止包括肛癌在内多种癌症的有效手段。欧盟的这一决定也为Gardasil保障更多人的健康提供了帮助。
详细英文报道：
GardasilmaybetheNo.2-sellingvaccineintheworld,butitsmarketershavestruggledagainstavarietyofbarrierstogetitwheretheywantitintermsofuptake.Now,anewanalcancerindicationinEuropemayhelpwiththatgoal.
OnWednesday,SanofiPasteurMSD--theEuropeanjointventurebetweenSanofi($SNY)andMerck($MRK)--announcedthattheEuropeanCommissionhadgreen-lightedGardasilinbothmalesandfemalesforthepreventionofanalcancersandprecancerouslesionsrelatedtocertainHPVtypes.Accordingtothecompany,about6,800newcasesofanalcanceroccureachyearinEurope,ofwhichbetween75%and80%areattributabletoHPVtypesthatGardasiltargets.
Thankstothenewindicationforanalcancer,Gardasilprovidestodayauniquepreventiontoolforsuchaseriousoncologicaldisease,SanofiPasteurMSDPresidentDr.Jean-PaulKresssaidinastatement.
ThenewusecouldalsohelpimprovethecaseforcoveringthevaccineforbothsexesinEurope;unlikeAustralia,whoseNationalHPVVaccinationProgramprovidesGardasilfreeforbothgirlsandboys,theU.K.,forone,onlycoversthevaccineforgirlsaged12to13.
ThepossibilitytopreventanalcancerfurtherreinforcestheneedforwidespreadvaccinationofbothmalesandfemalesagainstHPV,especiallysincetherearecurrentlynootherroutinemeasuresorscreeningprogramsavailableforpreventionofanalcancers,Kresssaid.
Anew,two-doseschedulecouldhelptothatendaswell.GiventhenodinAprilbytheEC,theregimenwillcutthenumberofdosesperpatientbyone,withsomesuggestingthecountryusethemoneysavedtoextenditsGardasilprogramtoboys.
MerckandSanofi,too,areoptimisticthatsuchaswitchwouldactuallyimprovesalesdespitelimitingper-patientshots,withaSanofiPasteurMSDspokeswomanrecentlytellingBritishmagazineGPthatthemovecouldhelptoextendHPVvaccinecoverageand
